Point-of-Care Regenerative Medicine and Autologous Biologics Market Analysis, 2026-2031 | Same-Day Orthobiologic Procedures Support Market Expansion
Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Point-of-Care Regenerative Medicine and Autologous Biologics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global point-of-care regenerative medicine and autologous biologics market was valued at USD 17.78 billion in 2025. It is projected to increase from USD 18.97 billion in 2026 to USD 28.61 billion by 2031, registering a compound annual growth rate of 8.56% during the 2026-2031 forecast period.
Market growth is supported by increasing demand for same-day autologous biologic procedures, expanding clinical use in orthopedics and sports medicine, and greater adoption across hospitals, ambulatory surgery centers, specialty clinics, and other outpatient settings. The market report provides value-based forecasts in USD and analyzes product types, applications, end users, and major geographic markets.
Same-Day Orthobiologic Procedures Support Market Expansion
Demand for single-session autologous treatments continues to rise as healthcare providers seek to reduce repeat visits, streamline clinical workflows, and lower total episode-of-care costs. This trend is particularly important in orthopedic and sports medicine procedures, where point-of-care processing can be incorporated into established surgical and outpatient workflows.
Clinical research also continues to evaluate outcomes associated with autologous biologic treatments. Evidence related to one-stage cartilage procedures, platelet-rich plasma, and bone marrow aspirate concentrate is influencing clinical decision-making, procurement strategies, and payer assessments. Training programs remain an important adoption factor because clinicians frequently continue using the preparation methods and processing platforms introduced during practical instruction.
Closed-System Processing Becomes a Procurement Priority
Closed-system centrifugation and processing technologies are increasingly favored in accredited hospitals and outpatient facilities. Providers are prioritizing controlled processing pathways that address contamination risk, procedural consistency, and handling variability. Platforms offering closed-circuit operation and higher platelet concentration are consequently gaining attention from clinicians and procurement teams.
Group purchasing organizations and hospital systems are also incorporating closed architecture into purchasing criteria. As a result, closed-system functionality is moving from a premium differentiator toward a standard requirement within regulated healthcare environments.
Clinical Evidence and Regulatory Complexity Remain Key Challenges
Clinical evidence varies across indications, patient populations, preparation techniques, and product categories. Comparative research has not consistently demonstrated the superiority of higher-cost bone marrow aspirate concentrate systems over platelet-rich plasma for certain applications, including knee osteoarthritis. Where clear comparative benefits are unavailable, payers and formulary committees may favor cost containment, increasing pricing pressure on manufacturers.
Regulatory ambiguity surrounding minimal manipulation and homologous use also affects commercialization. Vendors must navigate different approval pathways and compliance requirements across North America, Europe, Asia-Pacific, and other regional markets.
Product and Application Analysis
Platelet-rich plasma systems accounted for an estimated 34.55% of the market by product type in 2025. Their position reflects broad utilization across orthopedics, sports medicine, wound care, aesthetic medicine, dentistry, and oral surgery. Familiar clinical workflows, procedural versatility, and comparatively lower processing complexity are expected to keep platelet-rich plasma systems central to the market.
Bone marrow concentration systems represent the fastest-growing product segment and are forecast to expand at an 11.02% CAGR through 2031. Growth is associated with spinal fusion augmentation and complex joint procedures requiring higher progenitor cell concentrations. Adipose-derived cell processing systems are gaining traction in wound care and aesthetic medicine, while platelet-rich fibrin systems are becoming increasingly relevant in dentistry and oral surgery.
The report covers platelet-rich plasma systems, bone marrow concentration systems, adipose-derived cell processing systems, platelet-rich fibrin systems, and other autologous biologic concentration platforms. Applications include orthopedics and sports medicine, wound care, aesthetic medicine, dentistry and oral surgery, cardiovascular and vascular procedures, neurology, and other clinical uses.
End-user analysis includes hospitals, specialty and ambulatory surgery centers, orthopedic and sports medicine clinics, aesthetic clinics, dental clinics, and academic and research centers.
Regional Market Outlook
North America held an estimated 39.45% market share in 2025, making it the largest regional market. High orthopedic procedure volumes, an established ambulatory surgery center network, and continued adoption of premium closed-system platelet-rich plasma and bone marrow concentration platforms support regional demand. The United States remains the leading national market, while Canada and Mexico are advancing through hospital procurement initiatives and technology transfer.
Europe remains a strategically important market, led by Germany and the United Kingdom. Hospital-based platelet-rich plasma programs, private aesthetic medicine services, and demand for mechanically processed autologous systems contribute to regional activity. Market participants continue to navigate complex distinctions between advanced therapy medicinal product regulations and medical device pathways.
Asia-Pacific is forecast to be the fastest-growing regional market, expanding at a 12.45% CAGR through 2031. Japan's structured regulatory pathway, South Korea's technology development, and high procedure volumes in China and India are expected to drive growth. The Middle East, Africa, and South America offer additional opportunities through hospital modernization, private-pay aesthetic care, and medical tourism.
Key Topics Covered
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for Same-Day Orthobiologic Procedures
4.2.2 Rising Shift Toward Closed-System Point-of-Care Processing
4.2.3 Expanding Clinical Use in Orthopedics and Sports Medicine
4.2.4 Broader Adoption in Wound Care and Aesthetic Medicine
4.2.5 Reimbursement Pull From Outpatient and ASC Settings
4.2.6 Integration of Digital Workflow Tracking and Standardized Kit Protocols
4.3 Market Restraints
4.3.1 Variable Clinical Evidence Across Indications and Products
4.3.2 Regulatory Ambiguity Around Minimal Manipulation and Homologous Use
4.3.3 Physician Skill Dependence and Procedure Variability
4.3.4 Under-Reported Reimbursement Friction for Multi-Use Kits and Ancillary Supplies
4.4 Value/Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Product Type
5.1.1 Platelet-Rich Plasma Systems
5.1.2 Bone Marrow Concentration Systems
5.1.3 Adipose-Derived Cell Processing Systems
5.1.4 Platelet-Rich Fibrin Systems
5.1.5 Other Autologous Biologic Concentration Systems
5.2 By Application
5.2.1 Orthopedics and Sports Medicine
5.2.2 Wound Care
5.2.3 Aesthetic Medicine
5.2.4 Dentistry and Oral Surgery
5.2.5 Cardiovascular and Vascular Applications
5.2.6 Neurology and Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Specialty and Ambulatory Surgery Centers
5.3.3 Orthopedic and Sports Medicine Clinics
5.3.4 Aesthetic Clinics
5.3.5 Dental Clinics
5.3.6 Academic and Research Centers
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 India
5.4.3.3 Japan
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 APEX Biologix, LLC
6.3.2 Arthrex, Inc.
6.3.3 B. Braun SE
6.3.4 Bioventus Inc.
6.3.5 Bone Biologics Corporation
6.3.6 Celling Biosciences, Inc.
6.3.7 EmCyte Corporation
6.3.8 Johnson & Johnson
6.3.9 Jointechlabs, Inc.
6.3.10 Kuros Biosciences AG
6.3.11 Medtronic plc
6.3.12 Organogenesis Holdings Inc.
6.3.13 Orthocell Ltd.
6.3.14 Regen Lab SA
6.3.15 Royal Biologics, Inc.
6.3.16 Smith and Nephew plc
6.3.17 Stryker Corporation
6.3.18 Terumo Corporation
6.3.19 Vericel Corporation
6.3.20 Xtant Medical Holdings, Inc.
6.3.21 Zimmer Biomet Holdings, Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/3yj7hr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.